The Research Institute of McGill University Health Centre, Department of Medicine, McGill University, Montreal, Quebec, Canada.
Steroids. 2012 Nov;77(13):1327-34. doi: 10.1016/j.steroids.2012.08.019. Epub 2012 Sep 15.
Steroids metabolically derive from lipid cholesterol, and vertebrate steroids additionally derive from the steroid pregnenolone. Pregnenolone is derived from cholesterol by hydrolytic cleavage of the aliphatic tail by mitochondrial cytochrome P450 enzyme CYP11A1, located in the inner mitochondrial membrane. Delivery of cholesterol to CYP11A1 comprises the principal control step of steroidogenesis, and requires a series of proteins spanning the mitochondrial double membranes. A critical member of this cholesterol translocation machinery is the integral outer mitochondrial membrane translocator protein (18kDa, TSPO), a high-affinity drug- and cholesterol-binding protein. The cholesterol-binding site of TSPO consists of a phylogenetically conserved cholesterol recognition/interaction amino acid consensus (CRAC). Previous studies from our group identified 5-androsten-3β,17,19-triol (19-Atriol) as drug ligand for the TSPO CRAC motif inhibiting cholesterol binding to CRAC domain and steroidogenesis. To further understand 19-Atriol's mechanism of action as well as the molecular recognition by the TSPO CRAC motif, we undertook structure-activity relationship (SAR) analysis of the 19-Atriol molecule with a variety of substituted steroids oxygenated at positions around the steroid backbone. We found that in addition to steroids hydroxylated at carbon C19, hydroxylations at C4, C7, and C11 contributed to inhibition of cAMP-mediated steroidogenesis in a minimal steroidogenic cell model. However, only substituted steroids with C19 hydroxylations exhibited specificity to TSPO, its CRAC motif, and mitochondrial cholesterol transport, as the C4, C7, and C11 hydroxylated steroids inhibited the metabolic transformation of cholesterol by CYP11A1. We thus provide new insights into structure-activity relationships of steroids inhibiting mitochondrial cholesterol transport and steroidogenic cholesterol metabolic enzymes.
甾体化合物在代谢上来源于脂类胆固醇,脊椎动物甾体化合物另外来源于甾体孕烯醇酮。孕烯醇酮由胆固醇在内质网中的线粒体细胞色素 P450 酶 CYP11A1 通过脂肪尾部的水解裂解产生,该酶位于线粒体内膜中。胆固醇向 CYP11A1 的输送包含了类固醇生成的主要控制步骤,并且需要一系列跨越线粒体双层膜的蛋白质。该胆固醇转运机制的关键成员是完整的外线粒体膜转运蛋白(18kDa,TSPO),一种高亲和力的药物和胆固醇结合蛋白。TSPO 的胆固醇结合位点由一个进化上保守的胆固醇识别/相互作用氨基酸共识(CRAC)组成。我们小组的先前研究确定 5-雄烯-3β,17,19-三醇(19-Atriol)作为 TSPO CRAC 基序的药物配体,抑制胆固醇与 CRAC 结构域和类固醇生成的结合。为了进一步了解 19-Atriol 作为药物的作用机制以及 TSPO CRAC 基序的分子识别,我们对 19-Atriol 分子进行了结构-活性关系(SAR)分析,用各种取代的甾体化合物在甾体骨架周围的位置进行了氧化。我们发现,除了 C19 位羟基化的甾体化合物外,C4、C7 和 C11 位的羟基化也有助于抑制最小的类固醇生成细胞模型中的 cAMP 介导的类固醇生成。然而,只有 C19 位羟基化的取代甾体化合物对 TSPO、其 CRAC 基序和线粒体胆固醇转运具有特异性,因为 C4、C7 和 C11 位羟基化的甾体化合物抑制了 CYP11A1 对胆固醇的代谢转化。因此,我们为抑制线粒体胆固醇转运和类固醇生成胆固醇代谢酶的甾体化合物的结构-活性关系提供了新的见解。